Dataset Information

High-resolution proteomic analysis of medulloblastoma clinical samples identifies therapy resistant subgroups and MYC immunohistochemistry as a powerful outcome predictor

ABSTRACT: While international consensus and the 2021 WHO classification recognize multiple molecular medulloblastoma subgroups, these are difficult to identify in current clinical practice. As a result, biology driven risk stratification and therapy assignment for medulloblastoma constitutes a major challenge. Here, we report mass spectrometry analysis of clinical samples as a method for medulloblastoma subgroup discovery and identify MYC immunohistochemistry (IHC) as a clinically tractable method for improved risk stratification.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Brain

SUBMITTER: Christopher Hughes

LAB HEAD: Christopher Hughes

PROVIDER: PXD051319 | Pride | 2025-03-06

REPOSITORIES: pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	2024-02-21-reviewed-UP000005640-spikein.fasta	Fasta
	20240124_FaresMMFFPECohort_1B2I_dia_1.raw	Raw
	20240124_FaresMMFFPECohort_1B2I_dia_2.raw	Raw
	20240124_FaresMMFFPECohort_1B2I_dia_3.raw	Raw
	20240124_FaresMMFFPECohort_3H1C_dia_1.raw	Raw

Items per page:

1 - 5 of 172

Publications

High-resolution proteomic analysis of medulloblastoma clinical samples identifies therapy resistant subgroups and MYC immunohistochemistry as a powerful outcome predictor.

Delaidelli Alberto A Burwag Fares F Ben-Neriah Susana S Suk Yujin Y Shyp Taras T Kosteniuk Suzanne S Dunham Christopher C Cheng Sylvia S Okonechnikov Konstantin K Schrimpf Daniel D von Deimling Andreas A Ellezam Benjamin B Perreault Sébastien S Singh Sheila S Hawkins Cynthia C Kool Marcel M Pfister Stefan M SM Steidl Christian C Hughes Christopher C Korshunov Andrey A Sorensen Poul H PH

Neuro-oncology 20250305

<h4>Background</h4>While international consensus and the 2021 WHO classification recognize multiple molecular medulloblastoma subgroups, these are difficult to identify in clinical practice utilizing routine approaches. As a result, biology-driven risk stratification and therapy assignment for medulloblastoma remains a major clinical challenge. Here, we report mass spectrometry-based analysis of clinical samples for medulloblastoma subgroup discovery, highlighting a MYC-driven prognostic signatu ...[more]

PMID: 40040502

Similar Datasets

Project description:Fibro-adipogenic progenitors (FAPs) are emerging cellular components of the skeletal muscle regenerative environment. The alternative functional phenotype of FAPs - either supportive of muscle regeneration or promoting fibro-adipogenic degeneration - is a key determinant in the pathogenesis of muscular diseases, including Duchenne Muscular Dystrophy (DMD). However, the molecular regulation of FAPs is still unknown. We show here that an "HDAC-myomiR-BAF60 variant network" regulates the functional phenotype of FAPs in dystrophic muscles of mdx mice. Combinatorial analysis of gene expression microarray and genome-wide chromatin remodeling by Nuclease accessibility (NA)-seq revealed that HDAC inhibitors de-repress a "latent" myogenic program in FAPs from dystrophic muscles at early stages of disease progression. In these cells HDAC inhibition promoted the expression of two core components of the myogenic transcriptional machinery, MyoD and BAF60C, and upregulated the myomiRs (miRs) miR-1.2, miR-133 and miR-206, which target two alternative BAF60 variants (BAF60A and B) ultimately leading to the activation of a pro-myogenic program at the expense of the fibro-adipogenic phenotype. By contrast, FAPs from dystrophic muscles at late stages of disease progression displayed resistance to HDACi-induced chromatin remodeling at myogenic loci and fail to activate the pro-myogenic phenotype. These results reveal a previously unappreciated disease stage-specific bipotency of mesenchimal cells within the regenerative environment of dystrophic muscles. Resolution of such bi-potency by epigenetic interventions, such as HDACi, provides the molecular rationale for the in situ reprogramming of target cells to promote therapeutic regeneration of dystrophic muscles. miRNA modulation upon Histone Deacetylase inhibition in Fibro-Adipogenic Progenitors (FAPs) derived from young mdx mice was evaluated by small RNA-sequencing in 2 controls and 2 treated samples